A Phase 3 interventional study of optional ASA as comedication and placebo to ASA in Stroke and Secondary Prevention, sponsored by Boehringer Ingelheim. Completed at 569 sites in 42 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2019-09-06.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Stroke by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Stroke · Boehringer Ingelheim.
Among the 23 studies in Stroke by Boehringer Ingelheim, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 3, and was the 15th registered.
8,277 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →None of the 23 studies in Stroke by Boehringer Ingelheim is open now. The open studies under Stroke, anywhere →
Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 150 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,390 is above the median of 48 across 6,037 interventional studies indexed under Stroke.
Median enrollment 686 across the 12 interventional studies, 9,472 across the 11 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Stroke by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Further inclusion criteria apply.
Exclusion criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
Drug: optional ASA as comedication · Drug: placebo to ASA · Drug: dabigatran etexilate
All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
Drug: placebo to optional ASA as comedication · Drug: placebo to dabigatran etexilate · Drug: ASA 100 mg
optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
placebo to comparator drug
optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
placebo
active comparator drug
active drug
Adjudicated Recurrent Stroke
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: From randomisation until full follow up period, approximately 43 months.
First Major Bleed (Adjudicated)
First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or, * Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or, * Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Adjudicated Ischaemic Stroke
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: From randomisation until full follow up period, up to 43 months
Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: From randomisation until full follow up period, up to 43 months
Disabling Stroke
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: From randomisation until full follow up period, up to 43 months
All-cause Death
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: From randomisation until full follow up period, up to 43 months
Adjudicated Intracranial Hemorrhage
Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Adjudicated Fatal Bleed
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated.
Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Adjudicated Life-threatening Bleed
Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Any Bleed (Investigator-reported)
This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity. The annualised event rate represents the average number of events per patient during a 1-year period.
Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
This was randomised, active comparator, double-blind, 2 arms (1:1 ratio) event-driven Phase III trial in participants with embolic stroke of undetermined source (ESUS). Study was conducted at multiple centers in 42 countries between 3 Dec 2014 (first participant enrollment) and 14 August 2018 (last participant visit).
| Milestone | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Started | 2695 | 2695 |
| Completed | 2620 | 2623 |
| Not completed | 75 | 72 |
| Withdrew: Death | 56 | 58 |
| Withdrew: Lost to follow-up | 19 | 14 |
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Adjudicated Recurrent Stroke | 4.09 | 4.80 |
First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or, * Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or, * Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| First Major Bleed (Adjudicated) | 1.84 | 1.33 |
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Adjudicated Ischaemic Stroke | 3.97 | 4.71 |
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death | 4.80 | 5.40 |
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Disabling Stroke | 0.55 | 0.93 |
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| All-cause Death | 1.24 | 1.28 |
Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Adjudicated Intracranial Hemorrhage | 0.67 | 0.63 |
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Adjudicated Fatal Bleed | 0.00 | 0.05 |
Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Adjudicated Life-threatening Bleed | 0.76 | 0.91 |
This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity. The annualised event rate represents the average number of events per patient during a 1-year period.
| Annualised event rate (%/ year) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Any Bleed (Investigator-reported) | 15.21 | 11.64 |
Collected over Adverse Events (AE) and serious AE starting between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months. All-cause mortality reported from randomisation until full follow up period, approximately 43 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 56/2,695 (2.1%) | 724/2,676 (27.1%) | 306/2,676 (11.4%) |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 58/2,695 (2.2%) | 740/2,674 (27.7%) | 295/2,674 (11%) |
| Event | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 95/2676 | 97/2674 |
| Ischaemic strokeNervous system disorders | 47/2676 | 45/2674 |
| Transient ischaemic attackNervous system disorders | 46/2676 | 41/2674 |
| Cerebral infarctionNervous system disorders | 25/2676 | 42/2674 |
| Atrial fibrillation or atrial flutterCardiac disorders | 34/2676 | 29/2674 |
| EpilepsyNervous system disorders | 18/2676 | 25/2674 |
| Atrial fibrillationCardiac disorders | 24/2676 | 20/2674 |
| FallInjury, poisoning and procedural complications | 21/2676 | 9/2674 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 12/2676 | 19/2674 |
| PneumoniaInfections and infestations | 18/2676 | 14/2674 |
| Event | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 173/2676 | 170/2674 |
| Atrial fibrillationCardiac disorders | 136/2676 | 128/2674 |
Randomised set (RS): The RS consisted of all patients who were randomised, regardless of whether they took trial medication. The start date of the observation period for this population was the date of randomisation.
| Age, Continuous(Years) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | Total |
|---|---|---|---|
| Mean | 64.5 ± 11.44 | 63.9 ± 11.39 | 64.2 ± 11.42 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | Total |
|---|---|---|---|
| Female | 1001 | 986 | 1987 |
| Male | 1694 | 1709 | 3403 |
| Ethnicity (NIH/OMB)(Participants) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 281 | 268 | 549 |
| Not Hispanic or Latino | 2354 | 2371 | 4725 |
| Unknown or Not Reported | 60 | 56 | 116 |
| Race (NIH/OMB)(Participants) | Dabigatran Etexilate 110 or 150 Milligram (mg) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 20 | 31 |
| Asian | 631 | 597 | 1228 |
| Native Hawaiian or Other Pacific Islander | 2 | 4 | 6 |
| Black or African American | 54 | 40 | 94 |
| White | 1926 | 1966 | 3892 |
| More than one race | 10 | 12 | 22 |
| Unknown or Not Reported | 61 | 56 | 117 |
Showing the first 100 of 569 sites across 42 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Aug 2018, 44 months.
Results were first posted in Sep 2019, 1 year after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 44 months is close to that.
Counting every sponsor, half of 129 studies reached it within 44 months; a quarter within 27 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran